The NIH stopped recruiting for trials of tecovirimat against mpox after the drug was deemed not significantly more effective vs. placebo. Other antivirals against mpox are under development ...

Scientists warn monkeypox could become a serious global threat as it shows signs of sustained human-to-human transmission.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical ...

“Today’s announcement of a special cash dividend reflects the strength of our balance sheet and continued confidence in the future of our business,” said Diem Nguyen, Chief Executive Officer. “As we ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international ...

Common symptoms for Mpox include rash, fever, sore throat, headache, muscle aches, back pain, low energy, and swollen lymph nodes. Symptoms usually begin within a week but can start one to 21 days ...

Overall, mortality was lower, and lesions resolved faster than anticipated – regardless of whether participants received tecovirimat or placebo, according to the NIH. Tecovirimat was found to be ...

While these studies did not show statistical significance difference between tecovirimat and placebo at this primary endpoint, the PALM 007 results did signal potential benefits for patients ...